Institut Nuklearnej A Molekularnej Mediciny
Institut Nuklearnej A Molekularnej Mediciny is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Institut Nuklearnej A Molekularnej Mediciny?
The 2026-10-09 snapshot links Institut Nuklearnej A Molekularnej Mediciny to 1 distinct CTIS trials. Recorded services include Whole body scan 99mTc, Galium radiolabelling , PET CT, Lutecium administration. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Institut Nuklearnej A Molekularnej Mediciny?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Institut Nuklearnej A Molekularnej Mediciny conducted?
The linked trials record locations in 11 countries, including Austria, Belgium, Czechia, Germany, Spain. These are trial locations, not confirmed office locations or countries where Institut Nuklearnej A Molekularnej Mediciny delivered services.
What can this page tell me about Institut Nuklearnej A Molekularnej Mediciny's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Institut Nuklearnej A Molekularnej Mediciny. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Institut Nuklearnej A Molekularnej Mediciny